alexa New Opportunities For Use Of Novel, Small-molecule PERK Inhibitors | 69485
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

JOINT EVENT:19th Euro Congress on Cancer Science and Therapy & 25th Cancer Nursing & Nurse Practitioners Conference

Wioletta Rozpedek, Alicja Nowak, Dariusz Pytel, J Alan Diehl and Ireneusz Majsterek
Medical University of Lodz, Poland
Medical University of South Carolina, USA
Posters & Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956-C1-106
Abstract
The newest data reported that PERK/eIF2α/ATF4/CHOP signaling pathway, that has a dual pro-adaptive or pro-apoptotic role, has a significant impact on development and progression human diseases e.g. cancer, neurodegenerative diseases, diabetes mellitus type 2. We selected set of potential PERK inhibitors included 150,000 compounds by utilizing docking software. To evaluate their biological activity the time resolved fluorescence test was utilized. We obtained 209 compounds and their specific ability for the inhibition PERK was measured by evaluating PERK phosphorylation at a concentration range of 250 nM to 5000 nM of each inhibitor using the radioactive kinase assay. We selected 9 compounds that inhibited PERK at 1000 nM and higher concentrations and were the most suitable inhibitors for subsequent in vitro analysis. We utilized human neuroblastoma cell line SH-SY5Y that was treated with selected inhibitors at a concentrations range of 0.15 μM to 50 μM and with thapsigargin to evoke endoplasmic reticulum stress. Moreover, we had two positive controls: SH-SY5Y without inhibitors and without thapsigargin, and the second one without inhibitors, but treated with thapsigargin. Then, we extracted total cell proteins and measured PERK activity by evaluating the level of PERK substrate eIF2α phosphorylation using the Western blot technique. As a result, inhibitor marked number 8 had the highest biological activity and significant inhibition of eIF2α phosphorylation was noted at 25 μM and higher concentrations. In conclusion, our results suggest that use of small-molecule PERK inhibitors, as a multifunctional drug, may contribute to the development of groundbreaking anti-cancer therapy leading to apoptotic cell death of cancer cells.
This work was supported by grant PRELUDIUM no. 2015/19/N/NZ3/00055 from the National Science Centre, Poland and by grant HARMONIA no. 2013/10/M/NZ1/00280 from the National Science Centre, Poland.
Biography

Wioletta Rozpędek studied Biology at the University of Lodz, Poland. She is specialized in the field of Neurophysiology and Cell Biology. Currently, she is a PhD student in the Department of Clinical Chemistry and Biochemistry of Medical University of Lodz, Poland. She is working on molecular basis of cancer and neurodegenerative diseases associated with endoplasmic reticulum stress ad activation of PERK-dependent signaling pathways. Her area of focus includes use of small-molecule inhibitors as a novel therapy against Alzheimer’s disease and cancer.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7